SYLVANT® (siltuximab) Is the Preferred Treatment for iMCD

Siltuximab (SYLVANT®) is recommended by the National Comprehensive Cancer Network® (NCCN®) as the preferred treatment for idiopathic multicentric Castleman disease (iMCD). Siltuximab is also the first-line therapy recommended by the Castleman Disease Collaborative Network (CDCN) guidelines.

SYLVANT is the only therapy approved by the US Food and Drug Administration (FDA) for the treatment of people with multicentric Castleman disease (MCD) who are negative for human immunodeficiency virus (HIV) and human herpesvirus‑8 (HHV‑8).

The road to diagnosis can be a long and difficult one. It’s good to know that there’s a treatment backed by the largest and most robust clinical studies in iMCD to date.

Body painting that shows how idiopathic multicentric Castleman disease can attack the lymph system.


SYLVANT Neutralizes IL-6, Preventing a Cytokine Storm

Cytokines are powerful molecules that are normally secreted by the cells of the immune system in
response to infectious or noninfectious agents.

iMCD is linked to an elevation of one particular cytokine called interleukin-6, or IL-6. The cause of overproduction is unknown, but elevated levels can cause abnormal signaling and inflammation. In people with iMCD, increased levels of IL-6 can result in a cytokine storm, which can cause organ damage and other harmful conditions.

SYLVANT works by binding directly to IL-6 to prevent it from interacting with its target receptor, found on immune cells. SYLVANT has been shown to resolve the commonly observed symptoms of iMCD by neutralizing the effects of IL-6.

Graphic showing how excess amount of IL-6, found in people with idiopathic multicentric Castleman disease, can lead to the overactivation of immune cells.
right blue arrow
Graphic showing how excess amount of IL-6, found in people with idiopathic multicentric Castleman disease, can cause a cytokine storm.
right blue arrow
Graphic showing how SYLVANT (siltuximab) targets IL-6 to prevent it from causing a cytokine storm in people with idiopathic multicentric Castleman disease.


Getting Your Infusion

Graphic of a syringe. Doctors may have to perform blood tests to ensure all the parameters are met before beginning idiopathic multicentric Castleman disease treatment.

Before administering SYLVANT, your healthcare professional will perform blood tests to ensure that all treatment parameters are met before beginning therapy. The tests are performed before every infusion for the first 12 months, and then every 3 dosing cycles thereafter. If the criteria are not met, your treatment may get delayed. 

What to Expect

SYLVANT is an infusion administered at a hospital or an infusion center by a trained healthcare professional.

  • Graphic of clothes.

    Dress comfortably for your appointment, as your movement might be restricted during the infusion. If walking around is allowed, be sure to ask your healthcare professional first.

  • Graphic of a book.

    Bring a book, laptop, tablet, or other digital device to help you pass the time.

  • Graphic representing SYLVANT (siltuximab) intravenous infusion (IV) bag that is used in the treatment of idiopathic multicentric Castleman disease.

    SYLVANT is administered by intravenous infusion (IV) over 1 hour, every 3 weeks. Treatment should continue until it’s no longer effective.

  • Graphic of an error message.

    If this is your first time getting an infusion, try not to make any other commitments for the rest of the day, as you won’t know how your body will react to the infusion.

Once started, SYLVANT treatment will continue unless the symptoms of iMCD return.

finger icon with ribbon

Receiving Your SYLVANT Infusion From the Comfort of Your Home

icon comfort of home

At EUSA Pharma, your health is our priority. That is why we are expanding access to our treatments through our new home infusion program. Before you can begin your home infusion, you must receive your first SYLVANT infusion at a clinic or hospital. 

Please note, you still have the option to continue your treatment at a hospital, clinic, or infusion center. To enroll in home infusion, or for additional information, please contact your healthcare provider.


Common Side Effects With SYLVANT

Any medication can be associated with side effects, and they can vary from person to person. Here are some of the most common side effects observed in people taking SYLVANT:

  • Rash
  • Itchy skin
  • Upper respiratory tract infections
  • Swelling or accumulation of fluid
  • Elevated blood levels of uric acid, which is excreted through the urine
  • Weight gain

virtual consultation

If you have started taking SYLVANT and have been experiencing one of the side effects above, you should contact your doctor immediately. 

Image of a man on a laptop.

Related Content

Explore our interactive Discussion guide

Talking to Your Doctor